Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis
Septic Shock
About this trial
This is an interventional treatment trial for Septic Shock focused on measuring Therapeutic Plasma Exchange (TPE), Septic Shock, Severe Sepsis, Albumin, Fresh Frozen Plasma
Eligibility Criteria
Inclusion Criteria Adult patients (age ≥18) with a documented or strong clinical suspicion of infection that meets the definition of septic shock as per the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
Exhibiting two of the four clinical signs of inflammation:
- Core temperature > 38oC or < 36oC
- Heart rate > 90 beats per minute
- Respiratory rate > 20 breaths per minute, or PaCO2 < 32 mmHg, or mechanical ventilation
- White cell count > 12 x 109/L or < 4 x 109/L or > 10% immature neutrophils
We will further identify the subset with a hospital mortality in excess of 40%:
- >30 mls/kg fluid resuscitation
- Noradrenaline >0.1 ug/kg/min to maintain MAP> 65mmHg for at least 4 consecutive hours and present at initiation of TPE
- Lactate >2 mmol/l.
Exclusion Criteria Patients will be excluded in cases where death is deemed inevitable or imminent during admission and either the attending physician, patient or surrogate legal decision maker is not committed to active treatment.
Sites / Locations
- Peter Lougheed CentreRecruiting
- South Health CampusRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
TPE in Septic Shock
Reference Population
The patients in this arm will receive TPE
The patients will receive the standard of care for septic shock treatment